The Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) Consortium. Focusing on clinically relevant and applicable AI tools voor HPB disease.
🎄 Pancreas 2023 Wrapped! 🍾
🔟 October 2023: The use of radiomics 🤖 in pancreas surgery... future or present?!
🧐 Is radiomics already impacting your clinical practice? 🫵
This is the first tool to predict the risk of POPF 🐳
The first ever Radiomics 👾 preoperative fistula risk score !!!
Development 🇳🇱 and external validation 🇮🇹
🐳 The radiomics-based preop FRS performed similarly to the existing scores ( ROC 0.8)
💪 Great added value considering only CT derived data!
https://t.co/E6Brd9WDhv
Now in @BjsOpen!
Externally valid #radiomics pre-op fistula risk score (RAD-FRS) for Whipple! 🇮🇹🇳🇱
FIRST externally valid model ✅ Similar AUC (0.81) to (ua)FRS (0.79) in preop setting 📷
👏 @EwoutIngwersen, @JackieBereska and @PHAIRconsortium!
https://t.co/7jBtcfpGLR
Last week radiogist Håvard Bjørke Jenssen from 🇳🇴@Oslounivsykehus visited the 🇳🇱 @AmsterdamUMC HPB team!
Sharing and aligning HPB CT segmentation ✍️ strategies with Yung Nio, @JackieBereska@i_verpalen and others! 📸
Visit finalized with the annual @AmsterdamUMC HPB BBQ!
Last week radiogist Håvard Bjørke Jenssen from 🇳🇴@Oslounivsykehus visited the 🇳🇱 @AmsterdamUMC HPB team!
Sharing and aligning HPB CT segmentation ✍️ strategies with Yung Nio, @JackieBereska@i_verpalen and others! 📸
Visit finalized with the annual @AmsterdamUMC HPB BBQ!
The future of IPMN management 🍇 will be based on two pillars
🏛️ Biomarkers and AI
🤖 Twelve AI based models to assess the risk of malignancy already exist!
😢 Methodological quality and reliability still to be improved… let’s work on it!!
🆓 read 👉https://t.co/U84qBoSA7R
@EurPancClub#EPC2023@BorisJanssen on behalf of @PHAIRconsortium!
AI residual cancer burden (RCB) to evaluate impact of NAT in resected pancreatic cancer!
RCB 🔬
NAT vs. upfront: 2.2 vs. 10.3 mm2
p<0.0001
Survival 📈
Above vs. below median RCB: 24 vs. 30 months.
p=0.018
@EurPancClub#EPC2023@BorisJanssen on behalf of @PHAIRconsortium!
AI residual cancer burden (RCB) to evaluate impact of NAT in resected pancreatic cancer!
RCB 🔬
NAT vs. upfront: 2.2 vs. 10.3 mm2
p<0.0001
Survival 📈
Above vs. below median RCB: 24 vs. 30 months.
p=0.018
#EAHPBA2023@EAHPBA
Segmentation model for 🔬 residual pancreatic cancer following neoadjuvant therapy (ISGPP-2)!
Model based on 528 pt, 14 centers, 7 countries🇳🇱🇺🇸🇩🇪🇳🇴🇹🇷🇰🇷🇦🇺, 4 scanner types!
Validated with by-scanner internal-external cross-validation 📊! F1 score of 0.78!
#EAHPBA2023@EAHPBA
Segmentation model for 🔬 residual pancreatic cancer following neoadjuvant therapy (ISGPP-2)!
Model based on 528 pt, 14 centers, 7 countries🇳🇱🇺🇸🇩🇪🇳🇴🇹🇷🇰🇷🇦🇺, 4 scanner types!
Validated with by-scanner internal-external cross-validation 📊! F1 score of 0.78!